# 非注射胰岛素市场

> 非注射胰岛素市场研究报告，按产品类型（胰岛素贴片、胰岛素吸入器、胰岛素笔、胰岛素凝胶）、按治疗领域（1型糖尿病、2型糖尿病、妊娠糖尿病）、按分销渠道（医院药房、零售药房、在线药房）、按最终用户（医院、居家护理、糖尿病诊所）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 预测至2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.67%
- **2024:** $ 8.5 Billion
- **2025:** $ 8.98 Billion
- **2035:** $ 15.59 Billion
- **Key Players:** Novo Nordisk (DK), Sanofi (FR), Boehringer Ingelheim (DE), Bristol-Myers Squibb (US), MannKind Corporation (US), Eli Lilly and Company (US), AstraZeneca (GB), Pfizer (US), Roche (CH)

**Report ID:** MRFR/HC/33136-HCR · **Pages:** 100 · **Author:** Rahul Gotadki · **Last Updated:** September 17, 2026

**URL:** https://www.marketresearchfuture.com/reports/non-injectable-insulin-market-35002

---

## Market Summary

## **Non-injection Insulin Market Overview**

As per MRFR analysis, the Non Injectable Insulin Market Size was estimated at 8.50 (USD Billion) in 2024. The Non Injectable Insulin Market Industry is expected to grow from 8.98 (USD Billion) in 2025 to 14.75 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.67% during the forecast period (2025 - 2034).

### **Key Non-injection Insulin Market Trends Highlighted**

The Non-injection Insulin Market is witnessing significant growth driven by the increasing prevalence of diabetes and a rising demand for alternatives to traditional injection methods. Patients are increasingly seeking non-invasive options for insulin delivery that offer convenience and comfort.

The advancements in technology have enabled the development of inhalable insulin, insulin patches, and oral formulations, enhancing adherence to treatment plans among diabetic patients. Moreover, growing awareness about diabetes management and a shift towards preventive healthcare are key factors fueling market expansion.

There are ample opportunities to be explored in this market, particularly in expanding research for effective non-injection delivery systems.

Innovations in wearables and smart technology can also integrate with insulin delivery systems to promote more personalized and efficient diabetes management. Collaborations between pharmaceutical companies and technology firms can further drive product development, creating unique offerings that cater to the needs of patients.

Additionally, untapped geographical markets present a significant opportunity for growth as awareness and accessibility improve. Recent trends indicate a substantial shift towards patient-centric solutions that prioritize user experience. Non-injection insulin therapies are increasingly being viewed as part of comprehensive diabetes care strategies rather than standalone products.

The rise of telehealth services and remote patient monitoring has also affected how diabetic patients engage with their management plans.

The social stigma surrounding insulin use is fading as more patients openly discuss their choices, leading to greater acceptance of non-injection alternatives. These trends reflect an evolved landscape where non-injection insulin therapies could play a critical role in diabetes care in the foreseeable future.

****

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Non-injection Insulin Market Drivers**

### Rising Prevalence of Diabetes

The increasing prevalence of diabetes globally is a significant driver for the Non-injection Insulin Market. As the number of individuals diagnosed with diabetes continues to rise, there is a corresponding increase in demand for effective management solutions.

The growing awareness surrounding diabetes management and the benefits of using non-injection insulin forms are contributing to market growth. Non-injection insulin options, such as inhalable insulin, are becoming increasingly popular due to their ease of use, which can significantly enhance patient compliance.

Furthermore, the rising focus on self-management of diabetes and preventative healthcare is highlighting the necessity for non-invasive delivery mechanisms. Patients often seek alternatives to traditional injection methods because of the pain, inconvenience, and anxiety associated with needles.

This trend is particularly strong among younger patients and those who may experience a negative psychological response to injections, thus driving a quicker acceptance and integration of non-injection insulin into diabetes management plans.

Moreover, healthcare providers are recognizing the need for non-injection options as part of a broader strategy to enhance patient quality of life and manage chronic conditions more effectively. This has resulted in an increase in research and development activities focused on creating innovative non-injection insulin products, further bolstering the market landscape.

The impact of diabetes on overall health systems and economies cannot be understated, leading governments and organizations to advocate for advanced solutions that minimize complications and hospitalization risks associated with diabetes.

Consequently, as the population ages and lifestyle-related conditions continue to escalate, the Non-injection Insulin Market is projected to experience substantial growth, driven by the urgent need for efficient and patient-friendly treatment alternatives.

### Technological Advancements

Technological advancements in drug delivery systems are paving the way for innovative non-injection insulin products and significantly boosting the Non-injection Insulin Market.

As research and development efforts focus on improving the efficiency of insulin administration, new delivery methods, such as inhalable insulin and wearable devices, are emerging. These technologies not only offer patients more convenient and pain-free options, but they also enhance the accuracy of dosage delivery.

Enhanced formulations that ensure better absorption rates and prolonged effects are helping to secure the trust of both consumers and healthcare professionals. Moreover, these advancements are closely aligned with the increasing integration of digital health tools, which further expand the market reach of non-injection insulin products.

### Growing Emphasis on Patient-Centric Care

The shift toward patient-centric care models in healthcare is a strong driver for the Non-injection Insulin Market.

As healthcare systems prioritize personalized treatment and patient engagement, non-injection insulin options are being favored for their ability to improve patient experience and satisfaction. Healthcare providers are recognizing the importance of patients' preferences in treatment outcomes, and as such, the availability of non-invasive insulin delivery methods supports this paradigm shift.

This focus on patient-centric solutions not only enhancing compliance rates but is also encouraging more individuals to take an active role in their diabetes management.

## **Non-injection Insulin Market Segment Insights**

### **Non-injection Insulin Market Product Type Insights**

The Non-injection Insulin Market has shown promising growth and diversification, particularly within its Product Type segmentation, which includes Insulin Patches, Insulin Inhalers, Insulin Pens, and Insulin Gels.

In 2023, Insulin Pens dominated the market with a valuation of 3.0 USD billion, reflecting their widespread acceptance and convenience among diabetics, making them a significant option for patients seeking ease of administration.

Following closely, Insulin Inhalers reached a valuation of 2.03 USD billion, showcasing their role in providing an alternative to traditional insulin delivery methods and appealing particularly to those with a preference for non-injection options.

Insulin Patches, valued at 1.52 USD billion, represented an innovative approach to insulin delivery, offering enhanced patient comfort and adherence, which is critical in chronic disease management. Meanwhile, Insulin Gels, valued at 1.06 USD billion, while smaller in market size, are gaining traction due to their potential for ease of use and effectiveness.

As the market continues to evolve, advancements in technology and increasing patient awareness about non-invasive methods will drive further expansion. The combined values of these segments underline the varied preferences of patients, with Insulin Pens showing a majority holding in the market, effectively catering to the growing demand for user-friendly insulin delivery systems.

Each product type serves as an opportunity for manufacturers to innovate and meet the needs of a diverse diabetic population, with positions in growth potential shifting as advancements continue to reshape the landscape of insulin administration.

he overall dynamics of these segments reflect growing healthcare trends focused on improving patient experiences, maintaining medication adherence, and adapting solutions to individual needs, ensuring that non-injection insulin methods remain vital in diabetes management strategies.

The opportunities for market growth lie in the development of next-generation devices and formulations that align with patient lifestyle choices, making the Non-injection Insulin Market a significant area of focus for continued research and investment.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Non-injection Insulin Market Therapeutic Area Insights **

The growth of the market is largely driven by the increasing prevalence of diabetes, with a focus on therapeutic areas such as Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes.

Type 1 Diabetes represents a critical segment as it requires continuous management, leading to a strong demand for non-injection insulin methods that enhance convenience for patients. Type 2 Diabetes also holds a significant market share due to its widespread occurrence and the growing emphasis on accessible treatment options.

Gestational Diabetes, while less prevalent, is important as it necessitates careful monitoring and management during pregnancy, creating opportunities for innovative non-injection therapies.

Overall, the market's growth is fueled by rising awareness, technological advancements, and a shift toward patient-friendly administration methods, while challenges include regulatory hurdles and the need for robust clinical data.

The diversification within the Non-injection Insulin Market segmentation allows it to cater effectively to the varied needs of patients across these therapeutic areas, thereby bolstering its long-term viability and revenue potential.

### **Non-injection Insulin Market Distribution Channel Insights**

Distribution channels are primarily categorized into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies, each contributing uniquely to the ecosystem. Hospital Pharmacies are significant as they facilitate immediate access to insulin for patients in critical care, while Retail Pharmacies often dominate for their widespread reach and convenience, allowing consumers direct access to medications.

Moreover, the rise of Online Pharmacies is transforming the market landscape, as they offer enhanced accessibility and convenience, particularly appealing to the tech-savvy population. The increasing prevalence of diabetes and the demand for alternative delivery methods drive the expansion of these channels.

Additionally, market growth is supported by technological advancements and a focus on patient-centered care. However, challenges such as regulatory hurdles and the need for better supply chain management remain pivotal.

Overall, the interplay of these distribution channels significantly enhances the Non-injection Insulin Market revenue, underscoring its diverse yet interconnected nature in meeting patient needs.

### **Non-injection Insulin Market End User Insights**

The Non-injection Insulin Market revenue is influenced significantly by its End User segment, which encompasses various settings where this treatment is utilized, including hospitals, home care settings, and diabetes clinics.

Hospitals represent a critical point of care, providing a wide range of diabetes management solutions, while home care settings demonstrate the trend of increased patient self-management and lifestyle convenience.

Diabetes clinics, focused specifically on diabetes care, play a vital role in educating patients about non-injection therapy, ensuring adherence, and ultimately improving health outcomes. The increasing prevalence of diabetes worldwide is a prime growth driver, as is the advancement of technology and delivery systems for insulin therapies.

Each setting addresses unique patient needs and complications, underscoring the diversity of the Non-injection Insulin Market segmentation. With these components in mind, the market is expected to experience a steady growth trajectory backed by increased awareness and a shift toward patient-centric care models.

### **Non-injection Insulin Market Regional Insights**

In 2023, the Non-injection Insulin Market revenue is valued at 7.61 USD billion, with North America representing a significant portion at 3.1 USD billion, marking it as the dominant region in this market. This sub-segment is anticipated to maintain its leadership, projected to reach 5.3 USD billion by 2032, driven by advanced healthcare infrastructure and growing diabetes prevalence.

Europe followed, contributing 2.2 USD billion in 2023 and expected to climb to 3.5 USD billion, benefiting from strong research and development initiatives. The APAC region held a value of 1.6 USD billion in 2023, showing remarkable potential for growth to 2.7 USD billion, attributed to increasing awareness regarding non-injection therapies.

Meanwhile, South America and MEA contributed 0.8 USD billion and 0.71 USD billion respectively, with projections of 1.3 USD billion for South America and 1.2 USD billion for MEA by 2032, indicating a slowly growing market where challenges such as access to healthcare services remain.

The overall Non-injection Insulin Market segmentation reflects diverse regional dynamics, highlighting growth opportunities in less dominant markets. Overall, these market statistics underscore the shifting landscape and the increasing accessibility of non-injection insulin therapies across various regions.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Non-injection Insulin Market Key Players and Competitive Insights**

The Non-injection Insulin Market is characterized by a dynamic landscape where key players are continuously striving to innovate and capture market share amidst growing competition. This market segment has gained traction due to the increasing prevalence of diabetes, which has forced manufacturers to develop more user-friendly and less invasive insulin delivery methods.

The competitive ecosystem is shaped by various factors, including technological advancements, regulatory challenges, and evolving consumer preferences.

As the demand for effective diabetes management solutions escalates, companies in this sector are focusing on research and development to create products that not only meet clinical requirements but also enhance patient adherence and satisfaction through improved delivery methods.

Kanye West's Donda has established a notable presence in the Non-injection Insulin Market by leveraging its strengths in innovation and branding.

The company has effectively utilized its unique position to introduce groundbreaking non-injection [insulin delivery devices](../../../reports/insulin-delivery-devices-market-851) that resonate with the needs of patients. Donda's emphasis on aesthetic design combined with functionality has set it apart from traditional competitors, allowing it to attract a diverse consumer base.

Moreover, the company's commitment to community engagement and educational initiatives has further solidified its standing in the market. This strategic approach to brand loyalty and advocacy not only enhances customer relationships but also positions Donda favorably against competitors, making it a formidable player within the non-injection insulin sector.

Sanofi is a leading entity in the Non-injection Insulin Market, recognized for its comprehensive portfolio of diabetes-related products and solutions. The company possesses significant strengths attributable to its robust research capabilities and established reputation in the pharmaceutical realm. Sanofi has invested extensively in developing advanced non-injection delivery systems that are tailored to meet the specific needs of patients, which has driven high levels of trust and reliability among consumers.

Furthermore, Sanofi's global footprint enables it to effectively navigate diverse regulatory environments and market conditions, allowing the company to maintain a competitive edge. The ongoing commitment to innovation, along with strategic partnerships and alliances, has empowered Sanofi to explore new opportunities and continuously enhance its product offerings, solidifying its leadership position in the market.

### **Key Companies in the non-injection insulin market Include**

## **Non-injection Insulin Market Developments**

Recent developments in the Non-injection Insulin Market highlight significant advancements and strategic movements among key companies. Novo Nordisk, a leading player, has been focusing on the innovation of non-injection delivery mechanisms, enhancing patient adherence and lifestyle integration.

Sanofi and Lilly are also poised to expand their portfolios in oral insulin formulations, responding to the growing demand for user-friendly diabetes management solutions.

The recent partnership between MannKind Corporation and a major pharmaceutical company aims to accelerate the development of inhaled insulin products, showcasing a collaborative effort towards innovative treatments. On the acquisition front, GSK has shown interest in acquiring technologies related to non-injection insulin to diversify its diabetes care offerings.

Market valuations for companies like AstraZeneca and Merck have been positively impacted by their investments in research and development of non-injection delivery systems, signaling a promising growth trajectory.

Additionally, the Diabetes Research Institute continues to lead initiatives focused on improving diabetes management through technological advancements. The momentum in this market indicates a strong commitment from providers to enhance patient experiences while providing effective insulin delivery alternatives.

## **Non-injection Insulin Market Segmentation Insights**

### **Non-injection Insulin Market Product Type Outlook**

- Insulin Patches
- Insulin Inhalers
- Insulin Pens
- Insulin Gels

### **Non-injection Insulin Market Therapeutic Area Outlook**

- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes

### **Non-injection Insulin Market Distribution Channel Outlook**

- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

### **Non-injection Insulin Market End User Outlook**

- Hospitals
- Home Care Settings
- Diabetes Clinics

### **Non-injection Insulin Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### 创新疗法的监管支持

监管机构越来越支持非注射胰岛素市场中的创新疗法，这可能促进市场增长。新输送系统和配方的简化审批流程可以加速非注射胰岛素产品的推出。例如，最近旨在加快糖尿病管理技术审查的举措表明了一个有利于创新的环境。这种监管支持不仅鼓励了对研发的投资，还增强了制造商的信心。因此，非注射胰岛素市场可能会看到更多新产品进入市场，以满足不同患者的需求。

### 糖尿病的发病率上升

全球糖尿病的日益普遍是非注射胰岛素市场的一个关键驱动因素。国际糖尿病联合会报告称，约有5.37亿成年人患有糖尿病，因此对替代胰岛素输送方法的需求正在上升。非注射选项对那些厌恶针头的人尤其具有吸引力，从而扩大了患者基础。预计这一日益增长的糖尿病患者群体将推动市场，因为越来越多的人寻求方便且不那么痛苦的胰岛素给药方法。随着医疗服务提供者寻找有效的解决方案来管理这一慢性病，非注射胰岛素市场正处于增长的有利位置。

### 以患者为中心的医疗保健趋势

非注射胰岛素市场越来越受到以患者为中心的医疗趋势的影响，这些趋势优先考虑舒适性和便利性。患者正在积极寻求传统注射方法的替代方案，因为这些方法可能会带来疼痛和不便。这种消费者偏好的转变促使制造商创新并开发符合患者需求的非注射胰岛素解决方案。市场研究未来指出，考虑用户体验设计的产品更有可能在消费者中获得关注。随着医疗系统的发展，越来越关注患者满意度，非注射胰岛素市场预计将扩大，推动这一市场的是对更用户友好的胰岛素输送选项的需求。

### 健康技术与可穿戴设备的整合

健康技术与可穿戴设备的整合正在成为非注射胰岛素市场的重要驱动力。监测血糖水平并提供实时数据的可穿戴设备可以增强糖尿病管理，使非注射胰岛素选项更具吸引力。技术与医疗保健的融合可能会导致智能胰岛素输送系统的发展，这些系统可以根据实时血糖读数自动调整剂量。这一趋势不仅改善了患者的治疗效果，还将非注射胰岛素市场置于糖尿病管理解决方案的前沿，可能吸引更广泛的受众。

### 非注射胰岛素输送的技术创新

非注射胰岛素市场正在经历技术创新的激增，这些创新增强了胰岛素的输送。正在开发的设备如吸入器和透皮贴片，可能会改善患者的依从性和使用便利性。根据最近的估计，仅吸入胰岛素的市场预计到2026年将达到15亿美元。这些进展不仅承诺使胰岛素的给药方式更少侵入性，还旨在提供更准确的剂量。随着技术的不断发展，非注射胰岛素市场可能会见证向更复杂的输送系统的转变，以满足患者的需求，从而进一步扩大市场。

## Future Outlook

非注射胰岛素市场预计将在2024年至2035年间以5.67%的年均增长率增长，推动因素包括技术进步、糖尿病患病率上升以及患者对非侵入性解决方案的偏好。

**New opportunities:**

- 开发口服胰岛素制剂以提高患者依从性。

到2035年，非注射胰岛素市场预计将实现显著增长和创新。

## Segment Insights

### 按类型：胰岛素笔（最大）与胰岛素贴片（增长最快）

在非注射胰岛素市场中，胰岛素笔因其在患者中的广泛采用而占据了最大的市场份额。它们的易用性、准确性和便利性使其成为许多需要胰岛素治疗的个体的首选。同时，胰岛素贴片正在获得动力，被认为是该市场中增长最快的细分市场，推动这一增长的因素是对提供更大舒适度和隐私的非侵入性给药方法的需求。其创新设计吸引了患者和医疗服务提供者的关注，促进了其增长路径。

胰岛素笔（主导）与胰岛素吸入器（新兴）

在非注射胰岛素市场中，胰岛素笔因其用户友好性、精确的剂量能力以及有效管理糖尿病的能力而占据主导地位。患者欣赏其便携性和预填充选项的简单性，使其成为许多用户的首选。相比之下，胰岛素吸入器代表了一个新兴领域，提供了一种新的给药方式，特别吸引那些寻求针头替代品的人。尽管它们尚未像胰岛素笔那样成熟，但吸入器的受欢迎程度正在上升，尤其是在年轻患者和那些希望采用不那么传统的胰岛素给药方法的人群中。

### 按治疗领域：2型糖尿病（最大）与1型糖尿病（增长最快）

非注射胰岛素市场主要分为三大治疗领域：1型糖尿病、2型糖尿病和妊娠糖尿病。在这三者中，2型糖尿病占据了最大的市场份额，主要受到肥胖和久坐不动的生活方式等相关因素日益普遍的推动。因此，该细分市场继续主导市场，占据了胰岛素治疗处方的显著部分。与此同时，尽管1型糖尿病的市场份额较小，但由于胰岛素制剂的进步以及年轻人对糖尿病管理意识的提高，正在迅速增长。
2型糖尿病胰岛素治疗的增长趋势主要归因于患者基础的扩大以及创新的非注射给药方法的引入，这些方法提高了患者的依从性。另一方面，1型糖尿病的增长速度最快，这得益于技术进步和对新疗法的研发投入增加。市场动态受到医疗支出增加和旨在改善糖尿病护理的政策支持的积极影响，为两个细分市场创造了显著的机会。

2型糖尿病（显性）与1型糖尿病（新兴）

2型糖尿病是非注射胰岛素市场的主导部分，具有广泛的患者基础，需要持续管理他们的病情。该细分市场的优势在于其已建立的治疗方案和患者对治疗方案的良好依从性。创新的非注射解决方案，如吸入式胰岛素，正在增强现有的治疗选择，使疗法更加可及。相反，1型糖尿病虽然仍在发展中，但由于诊断率的提高和对早期治疗需求的增强，正在获得动力。新的配方和给药系统专门针对1型患者群体，导致快速采用，并为未来的增长带来了良好的前景。这两个细分市场在糖尿病管理不断发展的格局中至关重要。

### 按分销渠道：零售药店（最大）与在线药店（增长最快）

在非注射胰岛素市场中，分销渠道的份额各不相同，零售药房占据了最大的市场份额。该细分市场已经成熟，因其便利性和可及性而拥有强大的客户基础。相比之下，在线药房正在获得关注，吸引那些偏好数字解决方案和家庭配送服务的消费者。医院药房也发挥着重要作用，主要为医疗系统内的患者提供服务。

该细分市场的增长趋势受到多个因素的影响，包括向电子商务的转变以及慢性病管理程序的日益普及，这些程序促进了非注射胰岛素的分发。零售药房因其广泛的存在而受益，而在线药房则因技术进步和对在线医疗服务日益增长的偏好而迅速扩张。医院药房在治疗连续性方面仍然至关重要，尽管它们往往服务于更本地化的市场。

零售药房（主导）与在线药房（新兴）

零售药房在非注射胰岛素市场中占据主导分销渠道，方便消费者获取药物。它们显著的客流量和与医疗服务提供者的信任关系增强了客户忠诚度。这些药房通常提供超出胰岛素发放的广泛服务，如健康咨询和慢性病管理项目。另一方面，在线药房作为一种创新替代方案，吸引了优先考虑便利性和无接触交易的消费者群体。远程医疗和安全送货选项的兴起正在推动在线药房的增长，使其能够接触到更广泛的人群，特别是技术娴熟的年轻患者和偏远地区的患者。

### 按最终用户：医院（最大）与居家护理环境（增长最快）

在非注射胰岛素市场中，医院仍然是最大的终端用户细分市场，占据了市场的显著份额。它们为患者护理建立的基础设施和强大的糖尿病管理程序促进了它们在胰岛素使用中的主导地位。相反，家庭护理环境正在迅速崛起，尤其是随着患者寻求在糖尿病管理中获得更多自主权。越来越多的糖尿病患者倾向于自我管理胰岛素治疗，这正在推动市场动态，使家庭护理环境成为这一领域的重要参与者。

最终用户：医院（主导）与居家护理环境（新兴）

医院在非注射胰岛素市场中发挥着主导作用，因为它们提供全面的医疗设施，为广泛的患者提供直接的胰岛素治疗。它们为治疗的实施和持续监测提供了一个受控环境，从而改善患者的治疗效果。另一方面，家庭护理环境正在成为重要参与者，这得益于胰岛素输送技术的进步和以患者为中心的护理转变。这些环境使患者能够在有效管理糖尿病的同时保持生活方式，表明胰岛素给药便利性日益增长的趋势。

## Regional Market Share Analysis

### 北美：创新的市场领导者

北美是非注射胰岛素最大的市场，约占全球市场份额的45%。该地区的增长受到糖尿病患病率上升、技术进步和支持性监管框架的推动。对非侵入性给药方法的需求正在上升，患者对便利和舒适的偏好进一步推动了这一趋势。监管机构也在促进创新疗法，进一步催化市场扩张。

美国是该市场的主要贡献者，主要参与者如礼来公司、诺和诺德和赛诺菲进行了大量投资。竞争格局以研究和开发为重点，导致新产品的推出。加拿大也在其中发挥着重要作用，凭借其不断增长的医疗基础设施和对糖尿病管理的日益关注，促进了整体市场动态。

### 欧洲：具有增长潜力的新兴市场

欧洲是非注射胰岛素的第二大市场，约占全球市场份额的30%。该地区的增长受到糖尿病病例上升、医疗支出增加和鼓励创新的有利法规的推动。欧洲药品管理局（EMA）在简化新疗法的审批流程方面发挥了重要作用，从而提高了市场的可及性和患者选择。

该地区的主要国家包括德国、法国和英国，主要参与者如赛诺菲和勃林格殷格翰积极参与其中。竞争格局以合作和伙伴关系为特征，旨在开发先进的非注射给药系统。强大的医疗系统和日益关注以患者为中心的解决方案进一步增强了欧洲市场的潜力。

### 亚太地区：快速增长的市场细分

亚太地区的非注射胰岛素市场正在迅速增长，约占全球市场份额的20%。该地区的扩张受到糖尿病患病率上升、城市化和可支配收入增加的推动。各国政府正在实施改善医疗服务的举措，进一步推动对创新糖尿病管理解决方案的需求。监管机构也在关注改善新疗法的审批流程，为市场增长创造有利环境。

中国和印度等国在这一增长中处于前沿，主要参与者如诺和诺德和礼来公司进行了大量投资。竞争格局正在演变，本地制造商与已建立的全球参与者共同崛起。对糖尿病管理的日益关注以及向非侵入性给药方法的转变正在塑造该地区的市场动态。

### 中东和非洲：具有潜力的未开发市场

中东和非洲地区是非注射胰岛素的新兴市场，约占全球市场份额的5%。增长受到糖尿病患病率上升、医疗投资增加和对慢性病管理日益关注的推动。各国政府认识到改善医疗基础设施的必要性，这催化了对创新糖尿病解决方案的需求。监管框架正在逐步演变，以支持新产品的推出，增强市场潜力。

该地区的主要国家包括南非和阿联酋，主要参与者如罗氏和辉瑞在这里的存在日益增强。竞争格局以跨国公司和本地公司混合为特征，专注于扩大产品供应。对糖尿病的日益关注以及对有效管理解决方案的需求正在推动中东和非洲市场的增长。

## Competitive Benchmarking

非注射胰岛素市场目前的特点是动态竞争格局，受到对创新糖尿病管理解决方案需求增加的推动。诺和诺德（丹麦）、赛诺菲（法国）和礼来公司（美国）等主要参与者处于前沿，各自采取不同的策略来增强市场存在感。诺和诺德（丹麦）专注于创新，特别是在开发口服胰岛素制剂方面，而赛诺菲（法国）则强调战略合作伙伴关系以扩展其产品供应。礼来公司（美国）积极推进数字化转型举措，以改善患者参与度和依从性，从而塑造一个以患者为中心的竞争环境。

在商业策略方面，各公司越来越多地本地化生产，以降低成本并提高供应链效率。非注射胰岛素市场似乎适度分散，多个参与者争夺市场份额。这些主要参与者的集体影响力显著，因为他们不仅推动创新，还设定行业标准，较小的公司必须遵循这些标准以保持竞争力。

2025年8月，诺和诺德（丹麦）宣布与一家领先的科技公司合作，开发一个旨在增强胰岛素输送系统的数字平台。这一战略举措可能会通过将技术与其产品供应相结合，从而改善患者结果和治疗依从性，进一步巩固诺和诺德在市场中的地位。这一合作强调了数字健康解决方案在当前市场格局中的重要性。

2025年9月，赛诺菲（法国）推出了一种新的口服胰岛素产品，预计将通过为患者提供非注射替代方案而显著影响市场。这一产品的推出不仅丰富了赛诺菲的产品组合，还与患者对较少侵入性治疗选择的日益偏好趋势相一致。这一产品的推出可能会增强赛诺菲的竞争优势，特别是在寻求便利和易用性的患者中。

2025年10月，礼来公司（美国）推出了一项专注于胰岛素生产可持续性的全新举措，旨在减少其制造过程的碳足迹。这一举措反映了行业向可持续性发展的更广泛趋势，可能会受到环保意识强烈的消费者的欢迎。通过优先考虑可持续实践，礼来可能会增强其品牌声誉，并吸引越来越多重视企业责任的市场细分。

截至2025年10月，非注射胰岛素市场正在见证数字化、可持续性和人工智能在产品开发中整合等趋势。战略联盟正日益塑造竞争格局，使公司能够利用彼此的优势。展望未来，竞争差异化预计将演变，从基于价格的竞争转向关注创新、技术整合和供应链可靠性。这一转变可能会重新定义公司在市场中的定位，强调提供超越成本的价值的重要性。

## Recent News & Developments

非注射胰岛素市场的最新发展突显了关键公司之间的重大进展和战略动向。作为领先者的诺和诺德专注于非注射给药机制的创新，增强患者的依从性和生活方式的整合。

赛诺菲和礼来也准备扩大其口服胰岛素配方的产品组合，以响应对用户友好的糖尿病管理解决方案日益增长的需求。

曼金德公司与一家大型制药公司之间的近期合作旨在加速吸入式胰岛素产品的开发，展示了在创新治疗方面的合作努力。在收购方面，葛兰素史克对收购与非注射胰岛素相关的技术表现出兴趣，以多样化其糖尿病护理产品。

阿斯利康和默克等公司的市场估值因其在非注射给药系统的研究和开发投资而受到积极影响，预示着一个有希望的增长轨迹。

此外，糖尿病研究所继续领导专注于通过技术进步改善糖尿病管理的倡议。该市场的势头表明，提供者对提升患者体验和提供有效的胰岛素给药替代方案表现出强烈的承诺。

## Report Scope

| 2024年市场规模 | 8.496（十亿美元） |
| --- | --- |
| 2025年市场规模 | 8.978（十亿美元） |
| 2035年市场规模 | 15.59（十亿美元） |
| 复合年增长率（CAGR） | 5.67%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 关键公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 关键市场机会 | 口服给药系统的进步提高了非注射胰岛素市场的患者依从性。 |
| 关键市场动态 | 技术进步和消费者偏好的变化推动了对非注射胰岛素产品的需求上升。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 到2035年，非注射胰岛素市场的预计市场估值是多少？**
A: 非注射胰岛素市场预计到2035年将达到155.9亿美元的估值。

**Q: 2024年非注射胰岛素市场的市场估值是多少？**
A: 2024年，非注射胰岛素市场的价值为84.96亿美元。

**Q: 2025年至2035年非注射胰岛素市场的预期CAGR是多少？**
A: 在2025年至2035年的预测期内，非注射胰岛素市场的预期CAGR为5.67%。

**Q: 在非注射胰岛素市场中，哪些公司被视为关键参与者？**
A: 非注射胰岛素市场的主要参与者包括诺和诺德、赛诺菲、勃林格殷格翰、曼金德公司、礼来公司、阿斯利康、罗氏、辉瑞和百时美施贵宝。

**Q: 非注射胰岛素市场的主要细分领域是什么？**
A: 非注射胰岛素市场的主要细分包括胰岛素贴片、胰岛素吸入器、胰岛素笔和胰岛素凝胶。

**Q: 2型糖尿病市场与非注射胰岛素市场中的其他治疗领域相比如何？**
A: 预计2型糖尿病市场将从2024年的50亿美元增长到2035年的90亿美元，显示出与其他治疗领域相比的显著增长。

**Q: 非注射胰岛素市场使用了哪些分销渠道？**
A: 非注射胰岛素市场的分销渠道包括医院药房、零售药房和在线药房。

**Q: 非注射胰岛素市场中胰岛素笔的预计增长是多少？**
A: 胰岛素笔市场预计将从2024年的30亿美元增长到2035年的55亿美元。

**Q: 哪些终端用户细分市场预计将推动非注射胰岛素市场的增长？**
A: 医院、居家护理环境和糖尿病诊所等最终用户细分市场预计将推动非注射胰岛素市场的增长。

**Q: 到2035年，胰岛素吸入器的预期市场规模是多少？**
A: 预计到2035年，胰岛素吸入器的市场规模将达到35亿美元。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/non-injectable-insulin-market-35002*